Live
- BJP MP candidate Bharat Prasad visited the student who tried to commit suicide
- PM’s popularity in the fast lane: Autos with 'Har Dil Mein Modi' slogan spotted across Delhi
- Delhi-based political parties are like East India Company: Sukhbir Badal
- Golf: Diksha moves into Top-20 at South African Women’s Open
- KCR lashes out against BJP and Congress for destroying Telangana
- Dairy Science students visited the Milk cooling plant
- Moody feels Pant ahead in keepers’ race for T20 WC squad; Srikkanth picks Rahul over Samson as reserve keeper
- Thanking voters for extending 'unparalleled support' to NDA, PM Modi says second phase 'too good'
- Natural Relief for Menstrual Cramps: Beetroot Juice Recipe
- Asha Worker died in a road accident
Zydus gets USFDA nod for generic antacid
Representational Image
Zydus Lifesciences on Monday said it has received final approval from the US health regulator to market Famotidine tablets, an antacid, in the...
Zydus Lifesciences on Monday said it has received final approval from the US health regulator to market Famotidine tablets, an antacid, in the American market.
The company has received approval from the US Food and Drug Administration to market the drug in the strengths of 20mg and 40mg, the company said in a statement.
Famotidine is a histamine H2 receptor blocker, which works by reducing the amount of acid in the stomach. It is used to prevent and treat heartburn and other symptoms caused by excessive acid in the stomach.
The drug will be manufactured at the group's drug formulation facility at SEZ, Ahmedabad, Zydus Lifesciences stated.
As per IQVIA MAT April 2022, Famotidine tablets had a market size of USD 67 million in the US.
